15JSMO_Program_SP_0612.indd

Size: px

Start display at page:

Download "15JSMO_Program_SP_0612.indd"

とらふみもちやま
5 years ago
Views:

1 メディカルセミナー / モーニングセミナー / イブニングセミナーのご案内 Medical Seminar / Morning Seminar / Evening Seminar July 27(Thu)Medical Seminar / メディカルセミナー MeS-1 11:20~12:10 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Discussion, what are emerging issues in IO treatment? 徹底討論がん免疫治療今何が課題か Chair Yoichi Nakanishi Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University Speakers Kiyotaka Yoh Department of Thoracic Oncology, National Cancer Center Hospital East Hiroyoshi Nishikawa Division of Cancer Immunology Exploratory Oncology Research & Clinical Trial Center Research Institute National Cancer Center Department of Immunology Nagoya University Graduate School of Medicine Co-host AstraZeneca K.K. MeS-2 11:20~12:10 Room 3 ( 神戸国際展示場 2 号館 1F コンベンションホール北 ) New era of oncological treatment for metastatic colorectal cancer ~How to Translate Various Guidelines into Clinical Practice~ 大腸がん薬物療法の新展開 ~ 各種ガイドラインを臨床にどう活かすか?~ Chair Yoshito Komatsu Hokkaido University Hospital Cancer Center Speaker Kei Muro Department of Clinical Oncology and Outpatient Treatment Center, Aichi Cancer Center Hospital Co-host Takeda Pharmaceutical Company Limited MeS-3 11:20~12:10 Room 4 ( 神戸国際展示場 1 号館 2F Hall A) Metastatic Colorectal Cancer: From Disease Biology to Clinical Management Chair Kensei Yamaguchi Cancer Institute Hospital of Japanese Foundation for Cancer Research Speaker Fortunato Ciardiello Seconda Università di Napoli, Italy Co-host Merck Serono Co., Ltd.

2 MeS-4 11:20~12:10 Room 5 ( 神戸国際展示場 1 号館 2F Hall B) New Developments of Advanced Gastric Cancer Treatment Chair Narikazu Boku National Cancer Center Hospital Speaker Salah-Eddin Al-Batran Krankenhaus Nordwest, University Cancer Center Frankfurt, Germany Co-host Eli Lilly Japan K.K. MeS-5 11:20~12:10 Room 6 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Lenalidomide Based Treatment: New Treatment Concept of Transplant Ineligible Multiple Myeloma Chair Yasushi Takamatsu Internal Medicine/Division of Medical, Oncology, Hematology and Infectious Diseases, Fukuoka University Faculty of Medicine Speaker Thierry Facon CHRU de Lille-Hôspital Claude Huriez Rue Michel Polonovski, France Co-host Celgene K.K. MeS-6 11:20~12:10 Room 7 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Recent Updates On Diagnosis and Treatment of Pancreatic and Gastrointestinal Neuroendocrine Tumors -WHO2017 A new classification- 膵消化管神経内分泌腫瘍の最新の診断と治療 ~WHO2017 新分類を踏まえて~ Chair Tetsuhide Ito Neuroendocrine Tumor Centre, Sanno Hospital International University of Health and Welfare Speaker Susumu Hijioka Department of Gastroenterology Aichi Cancer Center Hospital Co-host Nobelpharma.Co.,Ltd. MeS-7 11:20~12:10 Room 8 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Optimal Treatment Strategies for EGFR mutation-positive NSCLC EGFR 遺伝子変異陽性肺がん ~ 最適な治療戦略を考える~ Chair Yuichi Takiguchi Department of Medical Oncology Graduate School of Medicine, Chiba University Speaker Nobuhiko Seki Teikyo University School of Medicine, Division of Medical Oncology Co-host CHUGAI PHARMACEUTICAL CO., LTD.

3 MeS-8 11:20~12:10 Room 9 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Treatment modality of soft tissue sarcoma and appropriate treatment with Pazopanib 悪性軟部腫瘍の治療とパゾパニブの適正使用 Chair Hironobu Minami Kobe University Graduate School of Medicine, Oncology/Hematology Speakers Yoshihiro Nishida Orthopaedic Surgery, Nagoya University Graduate School of Medicine Yuichi Ando Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital Co-host Novartis Pharma K.K. MeS-9 11:20~12:10 Room 10 ( 神戸国際会議場 1F メインホール ) Strategic choices in the management of metastatic colorectal cancer Chair Ichinosuke Hyodo Department of Gastroenterology, University of Tsukuba Speaker Eric Van Cutsem Gastroenterology/Digestive Oncology, Leuven Cancer Institute, University Hospitals Leuven, Belgium Co-host Chugai Pharmaceutical Co., Ltd. MeS-10 11:20~12:10 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Save a patient's life from febrile neutropenia! - Medical Team Challenge in Shikoku Cancer Center 発熱性好中球減少症から患者を守れ! ~ 四国がんセンター肺癌医療チームの挑戦 ~ Chair Seiji Niho Division of Thoracic Oncology, National Cancer Center Hospital East Speaker Naoyuki Nogami Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center Co-host Eli Lilly Japan K.K. MeS-11 11:20~12:10 Room 12 ( 神戸国際会議場 3F レセプションホール ) Therapy of relapsed myeloma: an update Chair Masahiro Kizaki Department of Hematology Saitama Medical Center Saitama Medical University Speaker Mohamad Mohty Saint-Antoine Hospital, University Pierre & Marie Curie, Paris, France Co-host Bristol-Myers Squibb K.K.

4 MeS-12 11:20~12:10 Room 13 ( 神戸国際会議場 5F 501 会議室 ) Folfirinox in pancreatic cancer: Present and future Chair Junji Furuse Department of Internal Medicine,Medical Oncology Kyorin University School of Medicine, Kyorin University Hospital Cancer Center Speaker Michel Ducreux Gustave Roussy, Department of Medical Oncology and University Paris Saclay Co-host Yakult Honsha Co.,Ltd. MeS-13 11:20~12:10 Room 14 ( 神戸国際会議場 5F 502 会議室 ) Current standards and unsolved question in the treatment of sarcoma in advance phase Chair Toshiyuki Kunisada Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Speaker Jean-Yves Blay Director of the Centre Léon Bérard Co-host TAIHO PHARMACEUTICAL CO.LTD. MeS-14 11:20~12:10 Room 15 ( 神戸国際会議場 5F 会議室 ) What is the current and future Treatment Strategy against EGFR positive lung cancer Chair Tomohide Tamura Pulmonary Medicine Department, St. Luke's International Hospital Speaker Yi-long Wu Guangdong Lung Cancer Institute, China Co-host Nippon Boehringer Ingelheim Co., Ltd. July 28(Fri)Medical Seminar / メディカルセミナー MeS-15 12:30~13:20 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Latest Advance and Perspective on Adjuvant Chemotherapy for Resected Colon Cancer -Challenge for International Harmonization and Precision Medicine- 結腸癌術後補助化学療法の最新知見と展望 ~ 世界標準化個別化医療 ~ Chair Akihito Tsuji Department of Clinical Oncology, Faculty of Medicine Kagawa University 辻 Speaker Takayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East Co-host Chugai Pharmaceutical Co., Ltd.

5 MeS-16 12:30~13:20 Room 3 ( 神戸国際展示場 2 号館 1F コンベンションホール北 ) Discussion, treatment strategy for T790M mutation positive lung cancer 討論 T790M 変異陽性肺癌の治療戦略 Chair Isamu Okamoto Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University Speakers Hiroaki Akamatsu Respiratory Medicine and Medical Oncology, Wakayama Medical University Hidetoshi Hayashi Department of Medical Oncology, Kindai university, Faculty of Medicine Co-host AstraZeneca K.K. MeS-17 12:30~13:20 Room 4 ( 神戸国際展示場 1 号館 2F Hall A) Guiding strategy of ALK positive NSCLC established in Japan 日本が導くALK 陽性肺癌の戦略 Chair Tetsuya Mitsudomi Department of Surgery, Division of Thoracic Surgery Kindai University Faculty of Medicine Speaker Yasushi Goto National Cancer Center Hospital Department of Thoracic Oncology Co-host CHUGAI PHARMACEUTICAL CO., LTD. MeS-18 12:30~13:20 Room 5 ( 神戸国際展示場 1 号館 2F Hall B) Future perspective of immuno checkpoint inhibitor in NSCLC Chair Kazuhiko Nakagawa Kindai University Faculty of Medicine Speaker Julie Renee Brahmer Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Co-host Bristol-Myers Squibb K.K. ONO PHARMACEUTICAL CO., LTD. MeS-19 12:30~13:20 Room 6 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Current topics of treatment strategies for patients with triple-negative breast cancer 周術期乳癌治療のTopics Chair Masataka Sawaki Aichi Cancer Center Speaker Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center Co-host Kyowa Hakko Kirin Co., Ltd.

6 MeS-20 12:30~13:20 Room 7 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Pathological Diagnosis and Treatment of Neuroendocrine Tumor 神経内分泌腫瘍の病理診断と治療 Chair Junji Furuse Department of Medical Oncology, Kyorin University School of Medicine Speakers Nobuyuki Ohike Department of Pathology, Showa University Fujigaoka Hospital Masafumi Ikeda Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East Co-host Novartis Pharma K.K. MeS-21 12:30~13:20 Room 8 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Optimal approach to treatment of RRMM -Approaches for continuous therapy and AE management- Chair Yasushi Takamatsu Division of Medical Oncology, Hematology and Infections Disease, Department of Internal Medicine, Fukuoka University Speaker Xavier Leleu Onco-Hematology Department Service d'hématologie et Thérapie Cellulaire Pôle Rétional de Cancérologie Hopital de La Milétrie, CHU, Poitiers, France Co-host Takeda Pharmaceutical Company Limited MeS-22 12:30~13:20 Room 9 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Optimal approach for patients with PD-L1+ NSCLC PD-L1 陽性非小細胞肺癌の治療戦略 Chair Yuichiro Ohe National Cancer Center Hospital, Department of Thoracic Oncology Speaker Koichi Azuma Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine Co-host MSD K. K. MSD Taiho Pharmaceutical Co., Ltd. MeS-23 12:30~13:20 Room 10 ( 神戸国際会議場 1F メインホール ) The current topics and future treatment strategy in mcrc Chair Kensei Yamaguchi Cancer Institute Hospital of Japanese Foundation for Cancer Research Speaker Josep Tabernero Vall d' Hebron University Hospital Co-host Eli Lilly Japan K.K.

7 MeS-24 12:30~13:20 Room 11 ( 神戸国際会議場 3F 国際会議室 ) What do you think? Future treatment strategy of Luminal HER2 MBC どうする? これからのLuminal HER2 MBC 治療戦略 Chair Junji Tsurutani Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan Speaker Yoichi Naito Division of Experimental Therapeutics/Breast and Medical Oncology, National Cancer Center Hospital East / Co-host Chugai Pharmaceutical Co., Ltd. MeS-25 12:30~13:20 Room 12 ( 神戸国際会議場 3F レセプションホール ) Global Strategies for the Treatment of EGFR Mutation Positive Patient Chair Nobuyuki Yamamoto Third Department of Internal Medicine, Division of Pulmonology and Medical Oncology, Wakayama Medical University Speaker Rafael Rosell Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital Co-host Nippon Boehringer Ingelheim Co., Ltd. MeS-26 12:30~13:20 Room 13 ( 神戸国際会議場 5F 501 会議室 ) Prevention and management of chemotherapy-induced oral mucositis 薬剤性口内炎の予防を含めたマネジメント Chair Hiroji Iwata Aichi Cancer Center, Department of Breast Oncology Speakers Shin-ichiro Hiraoka First Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University Naoki Niikura Tokai University School of Medicine, Department of Endocrine & Breast Surgery Co-host Novartis Pharma K.K. MeS-27 12:30~13:20 Room 14 ( 神戸国際会議場 5F 502 会議室 ) Multidisciplinary team care approach to management of skin disorders caused by molecular targeted therapies チーム医療で取り組む分子標的薬に起因する皮膚障害 Chair Makoto Kawashima Tokyo Women's Medical University Speakers Naoya Yamazaki National Cancer Center Hospital Chisato Kyomori St. Marianna University School of Medicine Co-host Takeda Pharmaceutical Company Limited

8 MeS-28 12:30~13:20 Room 15 ( 神戸国際会議場 5F 会議室 ) Current Treatment Strategies for SCCHN Chair Makoto Tahara National Cancer Center Hospital East Speaker Jan B. Vermorken Antwerp University Hospital Co-host Merck Serono Co., Ltd. July 29(Sat)Medical Seminar / メディカルセミナー MeS-29 13:00~13:50 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) The treatment strategy of NSCLC using anti-pd-1 antibody~how do we interpret the result of clinical trials to the clinical practice~? 抗 PD-1 抗体を用いた非小細胞肺癌の治療戦略 ~ 臨床試験結果をどう実臨床に反映するか?~ Chair Tetsuya Mitsudomi Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine Speaker Nobuyuki Yamamoto Division of Pulmonary Medicine & Medical Oncology Wakayama Medical University Co-host MSD K. K. MSD Taiho Pharmaceutical Co., Ltd. MeS-30 13:00~13:50 Room 3 ( 神戸国際展示場 2 号館 1F コンベンションホール北 ) Personalized treatment of non-small cell lung cancer, from cytotoxic agents, molecular targets to immunotherapy NSCLCの個別化治療 ~ 殺細胞性抗がん剤から分子標的薬免疫療法まで~ Chair Terufumi Kato Kanagawa Cancer Center Speaker Hossein Borghaei Thoracic Medical Oncology, Fox Chase Cancer Center Co-host Eli Lilly Japan K.K. MeS-31 13:00~13:50 Room 4 ( 神戸国際展示場 1 号館 2F Hall A) Recent Advances in Biology and Treatment of Myeloma Bone Disease 多発性骨髄腫骨病変の病態解明と治療の進歩 Chair Yasushi Takamatsu Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Speaker Masahiro Abe Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School Co-host Daiichi Sankyo Co., Ltd.

9 MeS-32 13:00~13:50 Room 5 ( 神戸国際展示場 1 号館 2F Hall B) Reflecting on last 15 years - EGFR-TKI - この15 年から考える - EGFR-TKI - Chair Kazuhisa Takahashi Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine Speakers Miyako Satouchi Department of Thoracic Oncology and Chemotherapy, Hyogo Cancer Center Satoshi Oizumi Department of Respiratory Medicine, Hokkaido Cancer Center Co-host AstraZeneca K.K. MeS-33 13:00~13:50 Room 6 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) The role of second generation ALK-TKI in ALK+ NSCLC Chair Yuichi Takiguchi Department of Medical Oncology, Graduate School of Medicine, Chiba University Speaker Christian Rolfo Phase I-Early Clinical Trials Unit / Clinical Trial Management Program, Oncology Department, University Hospital Antwerp, Belgium Co-host Novartis Pharma K.K. MeS-34 13:00~13:50 Room 7 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) New therapeutic strategies of neuroendocrine tumor 神経内分泌腫瘍の新たな治療戦略 Chair Takuji Okusaka National Cancer Center Hospital Speaker Tetsuhide Ito Sanno Hospital Internal University of Health and Welfare Co-host TEIJIN PHARMA LIMITED MeS-35 13:00~13:50 Room 8 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Key drug of later line chemotherapy in metastatic colorectal cancer Let s learn Regorafenib 大腸癌化学療法後方ラインのKey drug ~レゴラフェニブを知ろう~ Chair Kensei Yamaguchi The Cancer Institute Hospital Of Japanese Foundation for Cancer Research Speaker Satoshi Yuki Hokkaido University Hospital Co-host Bayer Yakuhin, Ltd.

10 MeS-36 13:00~13:50 Room 9 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) The medical oncologist's past and future role in perioperative and adjuvant chemotherapy for gastric cancer 腫瘍内科医が学ぶ胃癌周術期補助化学療法 Chair Kei Muro Department of Clinical Oncology,Aichi Cancer Center Hospital Speaker Machida Nozomu Division of Gastrointestinal Oncology, Shizuoka Cancer Center Co-host TAIHO PHARMACEUTICAL CO.LTD. MeS-37 13:00~13:50 Room 10 ( 神戸国際会議場 1F メインホール ) Mechanisms of Endocrine Resistance in ER+ Breast Cancer ER 陽性乳癌におけるホルモン療法耐性のメカニズム Chair Shigehira Saji Department of Medical Oncology, Fukushima Medical University Speaker Richard S. Finn Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, CA, USA Co-host Pfizer Japan Inc. MeS-38 13:00~13:50 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Follicular lymphoma current standards of the ESMO guidelines Chair Koji Izutsu Department of Hematology, National Cancer Center Hospital Speaker Martin Dreyling Department of Medicine III, University of Munich, Munich, Germany Co-host Chugai Pharmaceutical Co., Ltd. MeS-39 13:00~13:50 Room 12 ( 神戸国際会議場 3F レセプションホール ) Optimizing integration of genomics in cancer treatment approaches Chair Kazuto Nishio Department of Genome Biology, Kindai University Faculty of Medicine Speaker Tariq Mughal Vice-President, International Medical Affairs, Foundation Medicine Co-host Chugai Pharmaceutical Co., Ltd. MeS-40 13:00~13:50 Room 13 ( 神戸国際会議場 5F 501 会議室 ) Topics of palliative medicine / supportive care in medical oncology 腫瘍内科における緩和医療支持療法の話題 Chair Toshimi Takano Department of Medical Oncology, Toranomon Hospital Speaker Yoichi Naito Division of Experimental Therapeutics / Breast and Medical Oncology, National Cancer Center Hospital East / Co-host Hisamitsu Pharmaceutical Co., Inc. Kyowa Hakko Kirin Co., Ltd.

11 MeS-41 13:00~13:50 Room 14 ( 神戸国際会議場 5F 502 会議室 ) Clinincal questions and future perspective of immuno-oncology がん免疫療法のClinical Questionと将来展望 Chair Makoto Tahara Department of Head and Neck Medical Oncology National Cancer Center Hospital East Speaker Jiichiro Sasaki Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, KITASATO UNIVERSITY SCHOOL OF MEDICINE Co-host Bristol-Myers Squibb K.K. ONO PHARMACEUTICAL CO., LTD. MeS-42 13:00~13:50 Room 15 ( 神戸国際会議場 5F 会議室 ) Precision medicine in Lung Cancer: New possibility of Crizotinib 肺癌領域のPrecision medicine~クリゾチニブの新たな可能性 ~ Chair Takashi Seto Department of Thoracic Oncology,National Kyushu Cancer Center Speaker Koichi Goto Department of Thoracic Oncology, National Cancer Center Hospital East Co-host Pfizer Japan Inc. Merck Serono Co.,Ltd. July 28(Fri)Morning Seminar / モーニングセミナー MoS-1 7:20~8:10 Room 6 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Treatment of thyroid cancer by molecular target medicine 甲状腺癌における分子標的治療薬 Chair Makoto Tahara Division of Head and Neck Medical Oncology, National Cancer Center Hospital East Speaker Robert Haddad Head and Neck Oncology, Dana Farber Cancer Institute Co-host Eisai Co.,Ltd. MoS-2 7:20~8:10 Room 7 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Proteasome Inhibitors, Basic Research and Clinical Practice プロテアソーム阻害剤の基礎から臨床まで Chair Shinsuke Iida Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences Speaker Yusuke Furukawa Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University Co-host ONO PHARMACEUTICAL CO., LTD.

12 MoS-3 7:20~8:10 Room 8 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) The Successful Development and Future Perspective of the Nationwide Lung Cancer Genomic Screening Project in Japan (LC-SCRUM-Japan) 全国規模の肺癌遺伝子スクリーニングプロジェクト LC-SCRUM-Japan ~これまでの成果と今後の展望 ~ Chair Terufumi Kato Kanagawa Cancer Center Department of Thoracic Oncology Speaker Shingo Matsumoto National Cancer Center Hospital East Division of Thoracic Oncology Co-host Quintiles Transnational Japan K.K. MoS-4 7:20~8:10 Room 9 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Lung cancer related targeted therapy drugs and EGFR mutation testing ~The promising plasma testing 分子標的治療とEGFR 遺伝子変異検査血漿検査の果たす役割 Chair Miyako Satouchi Department of Thoratic Oncology, Hyogo Cancer Center Overcoming the resistance of EGFR inhibitors and expectation for liquid biopsy EGFR 阻害剤の耐性の克服と血漿検査への期待 Speaker Takayasu Kurata Department of Thoracic Oncology, Kansai Medical University Hospital The position of EGFR T790M testing and technical points for accurate result EGFR T790M 血漿検査の位置づけとポイント Speaker Koichi Azuma Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine Co-host Roche Diagnostics K.K. MoS-5 7:20~8:10 Room 10 ( 神戸国際会議場 1F メインホール ) 2nd-line chemotherapy against metastatic Colorectal Cancer (mcrc) -efficacy and safety of ZALTRAP, the new anti VEGF agent- 進行再発大腸癌に対する2 次化学療法 - 新規 VEGF 阻害剤ザルトラップの有効性と安全性 - Chair Kei Muro Department of Clinical Oncology, Aichi Cancer Center Hospital Speaker Takayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East Co-host Sanofi K.K. Yakult Honsha Co., Ltd.

13 MoS-6 7:20~8:10 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Management of tumor lysis syndrome(tls) 腫瘍崩壊症候群のマネジメント Chair Yasushi Takamatsu Internal Medicine /Division of Medical,Oncology,Hematology and Infectious Diseases Fukuoka University Faculty of Medicine Speaker Keita Kirito Department of Hematology and Oncology,University of Yamanashi Co-host Sanofi K.K. MoS-7 7:20~8:10 Room 12 ( 神戸国際会議場 3F レセプションホール ) Understanding gastrointestinal tumorigenesis through cooperation of genetic alterations and microenvironment 消化器がんにおける遺伝子変異と微小環境相互作用の解明と治療へのアプローチ Chair Kensei Yamaguchi Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR Speaker Masanobu Oshima Division of Genetics Cancer Research Institute, Kanazawa University Co-host Sumitomo Dainippon Pharma Co.,Ltd MoS-8 7:20~8:10 Room 13 ( 神戸国際会議場 5F 501 会議室 ) Cancer treatment of CV port roles and management がん治療におけるCVポートの役割とその管理 Chair Narikazu Boku National Cancer Center Hospital Gastrointestinal Medical Oncology Speaker Tsuyoshi Aramaki Shizuoka Cancer Center Interventional Radiology IVR Co-host Toray Medical Co.,Ltd Toray Industries,Inc. MoS-9 7:20~8:10 Room 14 ( 神戸国際会議場 5F 502 会議室 ) Multi-institutional survey results leading to ideal safe handling practice 多施設共同抗がん薬曝露実態調査から得られた理想のSafe Handling Chair Shigeki Koda National Institute of Occupational Safety and Health, Japan JNIOSH Speaker Kenjiro Aogi Division of Clinical Research Promotion, National Hospital Organization Shikoku Cancer Center Co-host Nippon Becton Dicikinson Company, Ltd

14 MoS-10 7:20~8:10 Room 15 ( 神戸国際会議場 5F 会議室 ) Molecular mechanism-based optimal treatment strategy for Differentiated Thyroid Cancer Impact of TKIs on primary organs - 分子メカニズムに基づいた甲状腺癌治療戦略 ~TKIが主要臓器に与える影響を考える ~ Chair Shunji Takahashi Department of Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research Speakers Yuichi Ando Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital Mikio Mukai Department of Cardiovascular Medicine, Onco-cardiology Unit / Department of Medical Checkup, Osaka Medical Center for Cancer and Cardiovascular Diseases Co-host Bayer Yakuhin, Ltd. July 29(Sat)Morning Seminar / モーニングセミナー MoS-11 7:20~8:10 Room 6 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Concept of ICI treatment for NSCLC in the second line setting 非小細胞肺癌の二次治療における免疫チェックポイント阻害剤の考え方 Chair Hiroshi Sakai Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan Speaker Makoto Maemondo Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine Co-host ONO PHARMACEUTICAL CO., LTD. Bristol-Myers Squibb K.K. MoS-12 7:20~8:10 Room 7 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Considerations for sequencing of therapy for metastatic castration resistant prostate cancer Chair Yoshiyuki Kakehi Department of Urology, Kagawa University Faculty of Medicine Speaker Celestia S. Higano Department of Medicine and Urology, University of Washington School of Medicine Co-host Astellas Pharma Inc.

15 MoS-13 7:20~8:10 Room 8 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) The current trend of CRPC -the treatment strategy from biology and real world practice- 去勢抵抗性前立腺癌の最新潮流ー病態と実診療から治療戦略を考えるー Chair Mikio Sugimoto Department of Urology, Kagawa University Faculty of Medicine Speakers Masaki Shiota Department of Urology, Graduate School of Medical Sciences, Kyushu University Ken-ichi Tabata Kitasato University School of Medicine Department of Urology Co-host Janssen Pharmaceutical K.K. AstraZeneca K.K. MoS-14 7:20~8:10 Room 9 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Diagnosis of myelodysplastic syndromes (MDS) 骨髄異形成症候群 (MDS) の診断 Chair Takahiro Suzuki Department of Hematology, Kitasato University School of Medicine Speaker Tomoko Hata Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Co-host NIPPON SHINYAKU CO.,LTD. MoS-15 7:20~8:10 Room 11 ( 神戸国際会議場 3F 国際会議室 ) New treatment options of R/R PTCL R/R PTCLにおける新しい治療選択肢 Chair Koji Izutsu National Cancer Center Hospital Department of Hematology Speaker Yoshinobu Maeda Department of Hematology and Oncology, Okayama University Hospital Co-host mundipharma K.K.

16 July 27(Thu)Evening Seminar / イブニングセミナー ES-1 16:50~17:40 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Better management of the later line treatment for mcrc -Roles of physicians and medical staff- 大腸癌後方ライン治療のより良いマネジメントを目指して - 医師 / メディカルスタッフそれぞれの役割 - Chair Yoshito Komatsu Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center Speaker Ken Shimada Division of Medical Oncology, Department of Medicine, Showa University Koto Toyosu Hospital Co-host TAIHO PHARMACEUTICAL CO.LTD. ES-2 16:50~17:40 Room 4 ( 神戸国際展示場 1 号館 2F Hall A) Safety of AVASTIN + Paclitaxel therapy for HER2-negative metastatic breast cancer in Japan HER2 陰性進行再発乳がんに対するアバスチン + パクリタキセル療法の日本における安全性 Chair Yutaka Yamamoto Department of Breast and Endocrine Surgery Graduate School of Medical Sciences Kumamoto University Speakers Masahiko Ikeda Fukuyama City Hospital Breast and Thyroid Surgery Naoto Kondo Nagoya City University Graduate School of Medical Sciences and Medical School Breast Surgery Co-host Chugai Pharmaceutical Co., Ltd. ES-3 16:50~17:40 Room 5 ( 神戸国際展示場 1 号館 2F Hall B) Rationale and clinical data for Immuno-oncology of head and neck cancer 頭頸部癌におけるがん免疫療法 : その背景にあるものと臨床データ Chair Makoto Tahara Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Japan Speaker Robert L. Ferris University of Pittsburgh Cancer Institute Co-host ONO PHARMACEUTICAL CO., LTD. Bristol-Myers Squibb K.K.

17 ES-4 16:50~17:40 Room 6 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Treatment strategy for Advanced squamous cell carcinoma of the lung 進行扁平上皮肺がんに対する治療戦略 Chair Kazuhiko Nakagawa Department of Medical Oncology, Kindai University Faculty of Medicine Speaker Nobuyuki Yamamoto Third Department of Internal Medicine, Wakayama Medical University Co-host Nichi-Iko Pharmaceutical Co., Ltd. ES-5 16:50~17:40 Room 7 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Update of reactivation of hepatitis B virus B 型肝炎の再活性化のUpdate Chair Masatoshi Kudo Department of Gastroenterology and Hepatology, Kinki University School of Medicine Speaker Masafumi Ikeda National Cancer Center Hospital East, Department of Hepatobiliary and Pancreatic Oncology Co-host Bristol-Myers Squibb K.K. ES-6 16:50~17:40 Room 8 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Palliative Care for Patients with Advance/Metastatic Cancer 進行がんの治療と緩和ケア Chair Shinji Ohno Breast Oncology Center, The Cancer Institute Hospital Of JFCR Speaker Akira Inoue Department of Palliative Medicine, Tohoku Univercity School of Medicine Co-host Nippon Kayaku Co.,Ltd. ES-7 16:50~17:40 Room 9 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Therapeutic Strategy of Genomic Biomarker Testing using Next-generation Sequencing in Lung Cancer Patients with Driver Gene Mutation 次世代シークエンサーを用いたドライバー変異陽性肺がんに対する新たな治療戦略 Chair Yoichi Nakanishi Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University Speaker Kiyotaka Yoh Department of Thoracic Oncology, National Cancer Center Hospital East Co-host Novartis Pharma K.K.

18 ES-8 16:50~17:40 Room 10 ( 神戸国際会議場 1F メインホール ) Why can't you give outpatient chemotherapy? ~Tips by four experts for administering outpatient chemotherapy beginning tomorrow~ なぜ外来で化学療法できないの? ~あすから外来化学療法が実践できる4 人のエキスパートによる秘訣 ~ Chair Noriyuki Katsumata Department of Medical Oncology, Nippon Medical School MUSASHI KOSUGI Hospital Speaker Hikaru Nakajima Hematology/Medical Oncology, St. Luke's University Hospital Lewis Katz School of Medicine at Temple University Hematology/Medical Oncology, St. Luke's University Hospital Lewis Katz School of Medicine at Temple University Discussant Michitaka Nagase Department of Medical Oncology, Saku Central Hospital Advanced Care Center Hisashi Ishikura Department of Surgery, Division of Thoracic Surgery, Tokushima Red Cross Hospital Takashi Saotome Department of Medical Oncology, Matsudo City Hospital Co-host Kyowa Hakko Kirin Co.,Ltd ES-9 16:50~17:40 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Reconsideration of treatment sequence in NSCLC without driver mutation Non-Driver Mutation NSCLC 治療シークエンスの再考 Chair Yuichiro Ohe National Cancer Center Hospital Deputy Director Chief Department of Thoracic Oncology Speaker Makoto Maemondo Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine Co-host CHUGAI PHARMACEUTICAL CO., LTD. ES-10 16:50~17:40 Room 12 ( 神戸国際会議場 3F レセプションホール ) HER2-positive metastatic breast cancer: current and future treatment HER2 陽性進行再発乳癌治療の現在と未来 Chair Shigehira Saji Department of Medical Oncology, Fukushima Medical University Speakers Toshimi Takano Department of Medical Oncology, Toranomon Hospital Norikazu Masuda Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital Co-host Eisai Co., Ltd.

19 ES-11 16:50~17:40 Room 13 ( 神戸国際会議場 5F 501 会議室 ) Essence of Cancer medicine: Communication Skills? or Arts? がん医療のエッセンス : コミュニケーションスキルかアートか Chairs Yusuke Uchitomi National Cancer Center Hospital Tatsuo Akechi Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences Patient preferred communication skills at the beginning and end of anticancer treatment 患者が望むコミュニケーションスキル : がん化学療法を始めるとき終えるとき Speaker Maiko Fujimori National Institute of Mental Health, National Center for Neurology & Psychiatry How to break bad news 悪いニュースの伝え方実際 Speaker Hideo Kunitoh Medical Oncology Department,Japanese Red Cross Medical Center Co-host Mochida Pharmaceutical Co.,LTD. Pfizer Japan Inc. ES-12 16:50~17:40 Room 14 ( 神戸国際会議場 5F 502 会議室 ) Applications of NGS in Precision Cancer Management プレジションメイディシンにおける次世代シーケンサーの臨床応用 Chair Sadakatsu Ikeda Tokyo Medical and Dental University Cancer Center Speaker Shu-Jen Chen Act Genomics Co., Ltd. Co-host Act Genomics Japan Co., Ltd. ACTmed., Ltd. ES-13 16:50~17:40 Room 15 ( 神戸国際会議場 5F 会議室 ) Challenge and Initiative toward Precision Medicine for Cancer Patients through the Nationwide Cancer Genome Screening Project 全国規模のがんゲノムスクリーニングに基づくがんPrecision Medicine 実現に向けた取り組み Chair Kei Muro Department of Clinical Oncology and Outpatient Treatment Center, Aichi Cancer Center Hospital Speaker Takayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East Co-host Thermo Fisher Scientific K.K.

Evening Seminar Day2 (July 20)

Evening Seminar Day2 (July 20) July 20 (Fri)Evening Seminar / イブニングセミナー ES-12 17:10~18:00 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Chair Chikashi Ishioka Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University